



UNIVERSITÀ DEGLI STUDI DI PARMA

# BioSketch

## Marco Radi




Associate Professor in Medicinal Chemistry  
**P4T Group**, Department of Pharmacy  
University of Parma  
Viale delle Scienze, 27/A, 43124 Parma – ITALY  
Phone: +39-0521-906080  
Fax: +39-0521-905006  
e-mail: [marco.radi@unipr.it](mailto:marco.radi@unipr.it)  
Webpage URL <http://p4t.farmacia.unipr.it>

1 of 3



Marco Radi (PhD) is Associate Professor in Medicinal Chemistry at the Department of Pharmacy of the University of Parma where he established, in collaboration with Gabriele Costantino, the drug discovery group P4T.



He studied at the University of Siena (MSc cum Laude in Medicinal Chemistry, 2000; PhD in Medicinal Chemistry, 2004), doing his doctoral studies in solid-phase synthesis and antiviral drug-discovery with Maurizio Botta. He then did postdoctoral research at the University of Georgia (with David C.K. Chu; 2005-2006) where he pioneered the application of sub-zero microwave assisted technology for the synthesis of antiviral and anticancer nucleosides. He returned to the University of Siena as postdoctoral researcher (2006-2010) and then as untenured Assistant Professor (2010-2011). In December 2011 he moved to the University of Parma as permanent Assistant Professor at the School of Pharmacy, where he was nominated Associate Professor in 2014.

Prof. Radi participated to different National (Programma per la Ricerca Regionale in Materia di Salute 2009; PRIN-2007; PRIN-2008) and International (CHAARM; ExCellENT-Hit; TRIoH; COST AngioKem) multidisciplinary research projects. He was involved in the exclusive agreements between the University of Siena and i) Virostatics Srl; ii) CNRS for the licensing of patented compounds. He was a co-author of four business plan, one of which (Lead Discovery Siena; LDS) won the 2009 edition of the Start Cup Toscana.

Prof. Radi is currently member of the Editorial Board of the Journal of Chemistry (since 2012), MC member of the COST Action CM1207 "GLISTEN" (since 2013) and Erasmus Delegate for the Department of Pharmacy (since 2012). He is member of the Department of Pharmacy and of the teacher board for the PhD programme "Drugs, Biomolecules and Health Products" at the University of Parma, where he supervise several undergraduates and PhD students in the field of medicinal chemistry. His present teaching activities are: i) Laboratory of drug analysis; ii) Database search for project planning. He is a peer reviewer for National (PRIN, FIRB, SIR) and International (IOFM, Horizon2020) research programs and referee for several medicinal chemistry and organic chemistry journals.

Prof. Radi's research activities are currently focused at the development of enterovirus/rhinovirus inhibitors (research sponsored by the Chiesi Foundation), kinase inhibitors, GPCRs modulators and Dengue virus inhibitors. His research interests are in the field of antiviral and anticancer drug discovery, with particular attention at the development of novel combinatorial methodologies to quickly produce highly functionalized chemical probes. He has authored more than 75 papers, book chapters and patent applications in these fields. A full list of publications is available [here](#).

#### Relevant publications:

- Vincetti P, Caporuscio F, Kaptein S, Gioiello A, Mancino V, Suzuki Y, Yamamoto N, Crespan E, Lossani A, Maga G, Rastelli G, Castagnolo D, Neyts J, Leyssen P, Costantino G, **Radi M.** "Discovery of multi-target antivirals acting on both the dengue virus NS5-NS3 interaction and the host Src/Fyn kinases" *J. Med. Chem.* 2015, *58*, 4964-



4975.

- **Radi M**, Tintori C, Musumeci F, Brullo C, Zamperini C, Dreassi E, Fallacara AL, Vignaroli G, Crespan E, Zanolì S, Laurenzana I, Filippi I, Maga G, Schenone S, Angelucci A, Botta M. "Design, Synthesis, and Biological Evaluation of Pyrazolo[3,4-d]pyrimidines Active in Vivo on the Bcr-Abl T315I Mutant." *J. Med. Chem.* 2013, 56, 5382-5394.
- **Radi M**, Evensen L, Dreassi E, Zamperini C, Caporicci M, Falchi F, Musumeci F, Schenone S, Lorens JB, Botta M. "A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation." *Bioorg. Med. Chem. Lett.* 2012, 22, 5579-5583.
- **Radi M**, Falchi F, Garbelli A, Samuele A, Bernardo V, Paolucci S, Baldanti F, Schenone S, Manetti F, Maga G, Botta M. "Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors." *Bioorg. Med. Chem. Lett.* 2012, 22, 2094-2098.
- **Radi M**, Brullo C, Crespan E, Tintori C, Musumeci F, Biava M, Schenone S, Dreassi E, Zamperini C, Maga G, Pagano D, Angelucci A, Bologna' M, Botta' M. "Identification of Potent c-Src Inhibitors Strongly Affecting the Proliferation of Human Neuroblastoma Cells" *Bioorg. Med. Chem. Lett.* 2011, 21, 5928-5933.
- **Radi M**, Dreassi E, Brullo C, Crespan E, Tintori C, Bernardo V, Valoti M, Zamperini C, Daigl H, Musumeci F, Carraro F, Naldini A, Filippi I, Maga G, Schenone S, Botta M. Design, Synthesis, Biological Activity and ADME Properties of Pyrazolo[3,4-d]pyrimidines Active in Hypoxic Human Leukemia Cells: a Lead Optimization Study" *J. Med. Chem.* 2011, 54, 2610-2626.
- **Radi M**, Maga G, Alongi M, Angeli L, Samuele A, Zanolì S, Bellucci L, Tafi A, Casaluce G, Giorgi G, Armand-Ugon M, González-Ortega E, Esté JA, Baltzinger M, Bec G, Dumas P, Ennifar E, Botta M. "Discovery of chiral cyclopropyl S-DABO derivatives as potent HIV-1 Reverse Transcriptase Inhibitors with improved potency against clinically relevant mutants" *J. Med. Chem.* 2009, 52, 840-851.
- Maga G, **Radi M**, Zanolì S, Manetti F, Cancio R, Hübscher U, Spadari S, Falciani C, Terrazas M, Vilarrasa J, Botta, M. "Discovery of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase (RT) Competing with the Nucleotide Substrate" *Angew. Chem. Int. Ed.* 2007, 46, 1810-1813.
- **Radi M**, Daft JR, Cho JH, Adema AD, Hoebe EK, Alexander LMM, Peters GJ, Chu CK. "In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,2-dioxolane-cytidine, prodrugs." *J. Med. Chem.* 2007, 50 (9), 2249-2253.